ILMN Fails To Light Up, MDGN Leaves The Big Board For Nasdaq, Watch Out For SUPN

(RTTNews) - Shares of Illumina Inc. (ILMN) were down more than 24% in extended trading on Monday after the company reported preliminary third quarter revenue that is lower than its previous forecast.

The company's estimated revenue for the third quarter of 2016 is now approximately $607 million, a 10% increase compared to $550 million in the year-ago quarter. But the company had previously forecast Q3, 2016 revenue to range between $625 million and $630 million.

Illumina is expected to report results for third quarter 2016 on Tuesday, November 1, 2016.

ILMN closed Monday's trading at $184.85, up 0.20%. In after-hours, the stock was down 24.29% to $139.95.

Medgenics Inc. (MDGN), listed on the New York Stock Exchange, has been given the go-ahead to list its shares on the NASDAQ Global Market, effective October 21, 2016.

The company expects that the move to NASDAQ will improve its stock visibility, enhance trading liquidity in its shares, and provide a greater exposure to leading biotech and healthcare institutional investors.

On the NASDAQ, Medgenics will continue to trade under its current ticker symbol, "MDGN".

MDGN closed Monday's trading at $5.46, up 4.20%.

Supernus Pharmaceuticals Inc. (SUPN) is scheduled to report results of its phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder on Tuesday, October 11, 2016, prior to the market open.

Initiated during 2015, the phase IIb dose-ranging trial of SPN-812 completed patient enrollment and last visit for the last patient occurred during the third quarter of this year. The company was initially expecting the phase IIb trial results to be available by early 2017.

SUPN closed Monday's trading at $24.69, up 3.83%. In after hours, the stock was up another 5.31% to $26.00.